This story is part of Forbes' coverage of Asia's Best Under A Billion 2018 list, which highlights 200 Asia-Pacific public companies with less than $1 billion in revenue and consistent top- and ...
In a deal that could net Medytox up to $362 million, the Seoul-based company will license to Allergan exclusive global rights outside Korea to develop and commercialize unspecified neurotoxin product ...
SILVER SPRING, Md.--(BUSINESS WIRE)--False statements about a botulinum toxin strain and concerns about integrity of data and the impact on patient safety are at the core of a Citizen Petition filed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback